Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|September 21, 2026

Why early development assessment is essential in modern biologics development

Author(s)Lonza

In biologics development, a strong scientific idea is only the beginning. A molecule may show compelling biology in discovery, demonstrate good target engagement, and generate early excitement internally or with investors, but none of this guarantees that it can become a safe, manufacturable, and clinically viable therapeutic. That is the reality many early-stage companies face, and it is exactly why early development assessment matters. Early drug development is complex, multidisciplinary, and shaped by interdependent decisions. Data from discovery, drug substance, drug product, immunology, analytics, safety, and regulatory activities must ultimately come together in the first-in-human enabling package. Read this content piece to explore how at Lonza, these connected workstreams are assessed in a coordinated way, helping teams build a more complete and decision-ready foundation for development.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.